Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shield Therapeutics PLC (GB:STX)
LSE:STX
Shield Therapeutics (STX) Share Price & Analysis
11 Followers
STX Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1.06p - 12.85p
Previous Close1.65p
Volume2.18M
Average Volume (3M)4.01M
Market Cap
£12.90M
Enterprise Value15.71M
Total Cash (Recent Filing)£2.82M
Total Debt (Recent Filing)£5.63M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding775,429,360
10 Day Avg. Volume1,011,904
30 Day Avg. Volume4,007,490
Standard Deviation0.24
R-Squared0.07
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-0.36
Price to Sales (P/S)7863.85
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Shield Therapeutics News
PremiumCompany Announcements
Shield Therapeutics AGM Yields Strong Support
PremiumCompany Announcements
Shield Therapeutics Eyes Expansion in Korea
PremiumCompany Announcements
Shield Therapeutics Reports Revenue Surge and Reduced Losses
PremiumCompany Announcements
Shield Therapeutics on Track for Positive Cashflow by 2025Options Prices
Currently, No data available
---
Ownership Overview
3.84% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
96.16% Public Companies and
Individual Investors
STX FAQ
What was Shield Therapeutics PLC’s price range in the past 12 months?
Shield Therapeutics PLC lowest share price was 1.06p and its highest was 12.85p in the past 12 months.
What is Shield Therapeutics PLC’s market cap?
Currently, no data Available
When is Shield Therapeutics PLC’s upcoming earnings report date?
Shield Therapeutics PLC’s upcoming earnings report date is Aug 07, 2024 which is in 34 days.
How were Shield Therapeutics PLC’s earnings last quarter?
Shield Therapeutics PLC released its earnings results on Apr 30, 2024. The company reported -0.026p earnings per share for the quarter, missing the consensus estimate of N/A by -0.026p.
Is Shield Therapeutics PLC overvalued?
According to Wall Street analysts Shield Therapeutics PLC’s price is currently Overvalued.
Does Shield Therapeutics PLC pay dividends?
Shield Therapeutics PLC does not currently pay dividends.
What is Shield Therapeutics PLC’s EPS estimate?
Shield Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shield Therapeutics PLC have?
Shield Therapeutics PLC has 782,056,400 shares outstanding.
What happened to Shield Therapeutics PLC’s price movement after its last earnings report?
Shield Therapeutics PLC reported an EPS of -0.026p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shield Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:STX
---
Shield Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.55%
12-Months-Change
Fundamentals
Return on Equity
-310.49%
Trailing 12-Months
Asset Growth
73.42%
Trailing 12-Months
Company Description
Shield Therapeutics PLC
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments which is based on key products include Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. It generates maximum revenue from Feraccru segment.
---
STX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---